Form 4: Cogent Biosciences CSO Sells 90,000 Shares

Cogent Biosciences' Chief Scientific Officer, John Edward Robinson, sold 90,000 shares of common stock for a weighted average price of $38.74 per share.

Summary

• John Edward Robinson, Chief Scientific Officer of Cogent Biosciences, Inc. (COGT), reported a sale of common stock.
• The transaction involved the disposition of 90,000 shares of common stock.
• The shares were sold on December 26, 2025, at a weighted average price of $38.74 per share.
• The sale was executed in multiple transactions with prices ranging from $38.51 to $39.01.
• Following this transaction, John Edward Robinson beneficially owns 140,002 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-scheduled sale.

Sentiment

Score: 5

Explanation: The filing is a standard disclosure of an insider stock sale, which is a neutral event in itself. The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily a reaction to new information.

Future Outlook

N/A

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide broader industry context or trends. Insider sales are common for various personal financial planning reasons, including diversification or liquidity.

Stakeholder Impact

• Shareholders may interpret the sale as a signal, though the Rule 10b5-1 plan suggests it was pre-planned for personal financial management rather than a reaction to company-specific news.

Key Dates

Recommendation

The sale of 90,000 shares by the Chief Scientific Officer, while significant in volume, was executed under a Rule 10b5-1 plan. This indicates a pre-scheduled transaction, often for personal financial planning, diversification, or liquidity, rather than a reactive sale based on new negative information about the company. Without additional context on the company's performance, strategic outlook, or other insider activity, this single transaction does not warrant a change from a 'hold' recommendation. Investors should monitor future filings and company performance for more comprehensive insights.

Keywords

Cogent Biosciences, COGT, John Edward Robinson, Chief Scientific Officer, Insider Sale, Form 4, Stock Transaction, Rule 10b5-1, Equity Disposition